Barre verticale Université de Lausanne - Unisciences
Séparateur Annuaire Séparateur Actualités Séparateur Aide Séparateur Login
Langues:  fr | en
Photo ambiance
UNIL > Unisciences >
de à
Données actuelles

Lluis Fajas Coll

Coordonnées Enseignements Publications  
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

92 publications

2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1985 |
β-Klotho deficiency shifts the gut-liver bile acid axis and induces hepatic alterations in mice.
Somm E., Henry H., Bruce S.J., Bonnet N., Montandon S.A., Niederländer N.J., Messina A., Aeby S., Rosikiewicz M., Fajas L. et al., 2018/11/01. American journal of physiology. Endocrinology and metabolism, 315 (5) pp. E833-E847. Peer-reviewed.
Dietary Fiber Confers Protection against Flu by Shaping Ly6c<sup>-</sup> Patrolling Monocyte Hematopoiesis and CD8<sup>+</sup> T Cell Metabolism.
Trompette A., Gollwitzer E.S., Pattaroni C., Lopez-Mejia I.C., Riva E., Pernot J., Ubags N., Fajas L., Nicod L.P., Marsland B.J., 2018/05/15. Immunity, 48 (5) pp. 992-1005.e8. Peer-reviewed.
Role of cell cycle regulators in adipose tissue and whole body energy homeostasis.
Lopez-Mejia I.C., Castillo-Armengol J., Lagarrigue S., Fajas L., 2018/03. Cellular and molecular life sciences, 75 (6) pp. 975-987. Peer-reviewed.
Cdkn2a deficiency promotes adipose tissue browning.
Rabhi N., Hannou S.A., Gromada X., Salas E., Yao X., Oger F., Carney C., Lopez-Mejia I.C., Durand E., Rabearivelo I. et al., 2018/02. Molecular metabolism, 8 pp. 65-76. Peer-reviewed.
CDK4, a new metabolic sensor that antagonizes AMPK.
Fajas L., Lopez-Mejia I.C., 2018. Molecular & cellular oncology, 5 (5) pp. e1409862. Peer-reviewed.
[DOI] [WoS] [Pmid] [serval:BIB_31B3469F93CE]
Chromatin immunoprecipitation improvements for the processing of small frozen pieces of adipose tissue.
Castellano-Castillo D., Denechaud P.D., Moreno-Indias I., Tinahones F., Fajas L., Queipo-Ortuño M.I., Cardona F., 2018. PloS one, 13 (2) pp. e0192314. Peer-reviewed.
E2F1 promotes hepatic gluconeogenesis and contributes to hyperglycemia during diabetes.
Giralt A., Denechaud P.D., Lopez-Mejia I.C., Delacuisine B., Blanchet E., Bonner C., Pattou F., Annicotte J.S., Fajas L., 2018. Molecular Metabolism, 11 pp. 104-112. Peer-reviewed.
Cancer: Linking Powerhouses to Suicidal Bags.
Martinez-Carreres L., Nasrallah A., Fajas L., 2017. Frontiers in Oncology, 7 p. 204. Peer-reviewed.
CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation.
Lopez-Mejia I.C., Lagarrigue S., Giralt A., Martinez-Carreres L., Zanou N., Denechaud P.D., Castillo-Armengol J., Chavey C., Orpinell M., Delacuisine B. et al., 2017. Molecular Cell, 68 (2) pp. 336-349.e6. Peer-reviewed.
E2F1, a Novel Regulator of Metabolism.
Denechaud P.D., Fajas L., Giralt A., 2017. Frontiers in endocrinology, 8 p. 311. Peer-reviewed.
Editorial: Metabolic Adaptation to Cell Growth and Proliferation in Normal and Pathological Conditions.
Giralt A., Fajas L., 2017. Frontiers in Endocrinology, 8 p. 362. Peer-reviewed.
Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma.
Morzyglod L., Caüzac M., Popineau L., Denechaud P.D., Fajas L., Ragazzon B., Fauveau V., Planchais J., Vasseur-Cognet M., Fartoux L. et al., 2017. Hepatology, 65 (4) pp. 1352-1368. Peer-reviewed.
The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway.
Khan AUH, Allende-Vega N., Gitenay D., Gerbal-Chaloin S., Gondeau C., Vo D.N., Belkahla S., Orecchioni S., Talarico G., Bertolini F. et al., 2017. Scientific Reports, 7 (1) p. 10654. Peer-reviewed.
CDK4 is an essential insulin effector in adipocytes.
Lagarrigue S., Lopez-Mejia I.C., Denechaud P.D., Escoté X., Castillo-Armengol J., Jimenez V., Chavey C., Giralt A., Lai Q., Zhang L. et al., 2016. Journal of Clinical Investigation, 126 (1) pp. 335-348.
[DOI] [Pmid] [serval:BIB_02D14093C661]
CDK4 is an essential insulin effector in adipocytes.
Lagarrigue S., Lopez-Mejia I.C., Denechaud P.D., Escoté X., Castillo-Armengol J., Jimenez V., Chavey C., Giralt A., Lai Q., Zhang L. et al., 2016. Journal of Clinical Investigation, 126 (1) pp. 335-348. Peer-reviewed.
E2F1 mediates sustained lipogenesis and contributes to hepatic steatosis.
Denechaud P.D., Lopez-Mejia I.C., Giralt A., Lai Q., Blanchet E., Delacuisine B., Nicolay B.N., Dyson N.J., Bonner C., Pattou F. et al., 2016. Journal of Clinical Investigation, 126 (1) pp. 137-150.
[DOI] [Pmid] [serval:BIB_3AE623148174]
KAT2B Is Required for Pancreatic Beta Cell Adaptation to Metabolic Stress by Controlling the Unfolded Protein Response.
Rabhi N., Denechaud P.D., Gromada X., Hannou S.A., Zhang H., Rashid T., Salas E., Durand E., Sand O., Bonnefond A. et al., 2016. Cell reports, 15 (5) pp. 1051-1061. Peer-reviewed.
Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner.
Zhang L., Tschumi B.O., Lopez-Mejia I.C., Oberle S.G., Meyer M., Samson G., Rüegg M.A., Hall M.N., Fajas L., Zehn D. et al., 2016. Cell Reports, 14 (5) pp. 1206-1217. Peer-reviewed.
Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells.
Scholz G., Jandus C., Zhang L., Grandclément C., Lopez-Mejia I.C., Soneson C., Delorenzi M., Fajas L., Held W., Dormond O. et al., 2016. Ebiomedicine, 4 pp. 50-61. Peer-reviewed.
Retinoblastoma Protein Knockdown Favors Oxidative Metabolism and Glucose and Fatty Acid Disposal in Muscle Cells.
Petrov P.D., Ribot J., López-Mejía I.C., Fajas L., Palou A., Bonet M.L., 2016. Journal of Cellular Physiology, 231 (3) pp. 708-718. Peer-reviewed.
Cell cycle regulation of mitochondrial function.
Lopez-Mejia I.C., Fajas L., 2015. Current Opinion in Cell Biology, 33 pp. 19-25. Peer-reviewed.
Metabolic adaptation to cancer growth: from the cell to the organism.
Escoté X., Fajas L., 2015. Cancer Letters, 356 (2 Pt A) pp. 171-175. Peer-reviewed.
Cell cycle regulation of mitochondrial function.
Lopez-Mejia IC Fajas L., 2014/11. Current Opinion in Cell Biology.
Antagonistic functions of LMNA isoforms in energy expenditure and lifespan.
Lopez-Mejia I.C., de Toledo M., Chavey C., Lapasset L., Cavelier P., Lopez-Herrera C., Chebli K., Fort P., Beranger G., Fajas L. et al., 2014. Embo Reports, 15 (5) pp. 529-539. Peer-reviewed.
Extracellular-signal-regulated kinase 5 modulates the antioxidant response by transcriptionally controlling Sirtuin 1 expression in leukemic cells.
Lopez-Royuela N., Rathore M.G., Allende-Vega N., Annicotte J.S., Fajas L., Ramachandran B., Gulick T., Villalba M., 2014. International Journal of Biochemistry and Cell Biology, 53 pp. 253-261. Peer-reviewed.
Metabolic control in cancer cells.
Fajas L., 2013. Annales d'endocrinologie, 74 (2) pp. 71-73.
Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth.
Fritz V., Benfodda Z., Henriquet C., Hure S., Cristol J.P., Michel F., Carbonneau M.A., Casas F., Fajas L., 2013. Oncogene, 32 (42) pp. 5101-5110.
Re-thinking cell cycle regulators: the cross-talk with metabolism.
Fajas L., 2013. Frontiers In Oncology, 3 p. 4.
E2F transcription factor-1 deficiency reduces pathophysiology in the mouse model of Duchenne muscular dystrophy through increased muscle oxidative metabolism.
Blanchet E., Annicotte J.S., Pradelli L.A., Hugon G., Matecki S., Mornet D., Rivier F., Fajas L., 2012. Human Molecular Genetics, 21 (17) pp. 3910-3917.
Mitochondrial T3 receptor p43 regulates insulin secretion and glucose homeostasis.
Blanchet E., Bertrand C., Annicotte J.S., Schlernitzauer A., Pessemesse L., Levin J., Fouret G., Feillet-Coudray C., Bonafos B., Fajas L. et al., 2012. Faseb Journal, 26 (1) pp. 40-50.
PPARγ contributes to PKM2 and HK2 expression in fatty liver.
Panasyuk G., Espeillac C., Chauvin C., Pradelli L.A., Horie Y., Suzuki A., Annicotte J.S., Fajas L., Foretz M., Verdeguer F. et al., 2012. Nature Communications, 3 p. 672. Peer-reviewed.
The RIP140 gene is a transcriptional target of E2F1.
Docquier A., Augereau P., Lapierre M., Harmand P.O., Badia E., Annicotte J.S., Fajas L., Cavaillès V., 2012. PLoS One, 7 (5) pp. e35839.
Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth.
Botton T., Puissant A., Cheli Y., Tomic T., Giuliano S., Fajas L., Deckert M., Ortonne J.P., Bertolotto C., Tartare-Deckert S. et al., 2011. Cell Death and Differentiation, 18 (1) pp. 109-121. Peer-reviewed.
E2F transcription factor-1 regulates oxidative metabolism.
Blanchet E., Annicotte J.S., Lagarrigue S., Aguilar V., Clapé C., Chavey C., Fritz V., Casas F., Apparailly F., Auwerx J. et al., 2011. Nature Cell Biology, 13 (9) pp. 1146-1152.
E2F1 at the crossroad of proliferation and oxidative metabolism.
Fajas L., Annicotte J.S., 2011. Cell Cycle, 10 (24) pp. 4193-4194.
Le double jeu des régulateurs du cycle cellulaire: contrôle de la prolifération et du métabolisme [Emerging key role of cell cycle regulators in cell metabolism].
Lagarrigue S., Blanchet É., Annicotte J.S., Fajas L., 2011. Médecine Sciences, 27 (5) pp. 508-513.
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.
Fritz V., Benfodda Z., Rodier G., Henriquet C., Iborra F., Avancès C., Allory Y., de la Taille A., Culine S., Blancou H. et al., 2010. Molecular Cancer Therapeutics, 9 (6) pp. 1740-1754. Peer-reviewed.
CDK4, pRB and E2F1: connected to insulin.
Fajas L., Blanchet E., Annicotte J.S., 2010. Cell Division, 5 (1) p. 6.
Cyclin G2 regulates adipogenesis through PPAR gamma coactivation.
Aguilar V., Annicotte J.S., Escote X., Vendrell J., Langin D., Fajas L., 2010. Endocrinology, 151 (11) pp. 5247-5254.
Cycling through metabolism.
Aguilar V., Fajas L., 2010. EMBO Molecular Medicine, 2 (9) pp. 338-348.
Metabolism and proliferation share common regulatory pathways in cancer cells.
Fritz V., Fajas L., 2010. Oncogene, 29 (31) pp. 4369-4377.
Persistent organic pollutant exposure leads to insulin resistance syndrome.
Ruzzin J., Petersen R., Meugnier E., Madsen L., Lock E.J., Lillefosse H., Ma T., Pesenti S., Sonne S.B., Marstrand T.T. et al., 2010. Environmental Health Perspectives, 118 (4) pp. 465-471.
The CDK4-pRB-E2F1 pathway : A new modulator of insulin secretion.
Fajas L., Blanchet E., Annicotte J.S., 2010. Islets, 2 (1) pp. 51-53.
Cell cycle regulators in the control of metabolism.
Blanchet E., Annicotte J.S., Fajas L., 2009. Cell Cycle, 8 (24) pp. 4029-4031.
CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance.
Chavey C., Lazennec G., Lagarrigue S., Clapé C., Iankova I., Teyssier J., Annicotte J.S., Schmidt J., Mataki C., Yamamoto H. et al., 2009. Cell Metabolism, 9 (4) pp. 339-349.
CXCL5 drives obesity to diabetes, and further.
Chavey C., Fajas L., 2009. Aging, 1 (7) pp. 674-677.
Downregulation of protein tyrosine phosphatase PTP-BL represses adipogenesis.
Glondu-Lassis M., Dromard M., Chavey C., Puech C., Fajas L., Hendriks W., Freiss G., 2009. International Journal of Biochemistry and Cell Biology, 41 (11) pp. 2173-2180.
In vitro and in vivo anti-melanoma effects of ciglitazone.
Botton T., Puissant A., Bahadoran P., Annicotte J.S., Fajas L., Ortonne J.P., Gozzerino G., Zamoum T., Tartare-Deckert S., Bertolotto C. et al., 2009. Journal of Investigative Dermatology, 129 (5) pp. 1208-1218.
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.
Clapé C., Fritz V., Henriquet C., Apparailly F., Fernandez P.L., Iborra F., Avancès C., Villalba M., Culine S., Fajas L., 2009. PLoS One, 4 (10) pp. e7542.
The CDK4-pRB-E2F1 pathway controls insulin secretion.
Annicotte J.S., Blanchet E., Chavey C., Iankova I., Costes S., Assou S., Teyssier J., Dalle S., Sardet C., Fajas L., 2009. Nature Cell Biology, 11 (8) pp. 1017-1023.
Regulator of G protein signaling-4 controls fatty acid and glucose homeostasis.
Iankova I., Chavey C., Clapé C., Colomer C., Guérineau N.C., Grillet N., Brunet J.F., Annicotte J.S., Fajas L., 2008. Endocrinology, 149 (11) pp. 5706-5712.
Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabesity because of increased energy expenditure.
Dali-Youcef N., Mataki C., Coste A., Messaddeq N., Giroud S., Blanc S., Koehl C., Champy M.F., Chambon P., Fajas L. et al., 2007. Proceedings of the National Academy of Sciences of the United States of America, 104 (25) pp. 10703-10708.
Rôle de PPARgamma dans la croissance du cancer de la prostate: de nouvelles pistes thérapeutiques .
Annicotte J.S., Culine S., Fajas L., 2007. Bulletin du Cancer, 94 (2) pp. 135-137.
The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes independently of PPAR gamma activation in human white adipocytes.
Mazzucotelli A., Viguerie N., Tiraby C., Annicotte J.S., Mairal A., Klimcakova E., Lepin E., Delmar P., Dejean S., Tavernier G. et al., 2007. Diabetes, 56 (10) pp. 2467-2475.
Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis.
Iankova I., Petersen R.K., Annicotte J.S., Chavey C., Hansen J.B., Kratchmarova I., Sarruf D., Benkirane M., Kristiansen K., Fajas L., 2006. Molecular Endocrinology, 20 (7) pp. 1494-1505.
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Annicotte J.S., Iankova I., Miard S., Fritz V., Sarruf D., Abella A., Berthe M.L., Noël D., Pillon A., Iborra F. et al., 2006. Molecular and Cellular Biology, 26 (20) pp. 7561-7574.
Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.
Bouaboula M., Hilairet S., Marchand J., Fajas L., Le Fur G., Casellas P., 2005. European Journal of Pharmacology, 517 (3) pp. 174-181.
Atypical transcriptional regulators and cofactors of PPARgamma.
Miard S., Fajas L., 2005. International Journal of Obesity, 29 Suppl 1 pp. S10-S12.
Cdk4 promotes adipogenesis through PPARgamma activation.
Abella A., Dubus P., Malumbres M., Rane S.G., Kiyokawa H., Sicard A., Vignon F., Langin D., Barbacid M., Fajas L., 2005. Cell Metabolism, 2 (4) pp. 239-249.
Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma.
Sarruf D.A., Iankova I., Abella A., Assou S., Miard S., Fajas L., 2005. Molecular and Cellular Biology, 25 (22) pp. 9985-9995.
Study of a new PPARgamma2 promoter polymorphism and haplotype analysis in a French population.
Meirhaeghe A., Tanck M.W., Fajas L., Janot C., Helbecque N., Cottel D., Auwerx J., Amouyel P., Dallongeville J., 2005. Molecular Genetics and Metabolism, 85 (2) pp. 140-148.
The nuclear receptor liver receptor homolog-1 is an estrogen receptor target gene.
Annicotte J.S., Chavey C., Servant N., Teyssier J., Bardin A., Licznar A., Badia E., Pujol P., Vignon F., Maudelonde T. et al., 2005. Oncogene, 24 (55) pp. 8167-8175.
Impaired pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/- )mice.
Fajas L., Annicotte J.S., Miard S., Sarruf D., Watanabe M., Auwerx J., 2004. Journal of Clinical Investigation, 113 (9) pp. 1288-1295.
A functional polymorphism in a STAT5B site of the human PPAR gamma 3 gene promoter affects height and lipid metabolism in a French population.
Meirhaeghe A., Fajas L., Gouilleux F., Cottel D., Helbecque N., Auwerx J., Amouyel P., 2003. Arteriosclerosis, Thrombosis, and Vascular Biology, 23 (2) pp. 289-294.
Adipogenesis: a cross-talk between cell proliferation and cell differentiation.
Fajas L., 2003. Annals of Medicine, 35 (2) pp. 79-85.
PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner.
Fajas L., Egler V., Reiter R., Miard S., Lefebvre A.M., Auwerx J., 2003. Oncogene, 22 (27) pp. 4186-4193.
Selective cyclo-oxygenase-2 inhibitors impair adipocyte differentiation through inhibition of the clonal expansion phase.
Fajas L., Miard S., Briggs M.R., Auwerx J., 2003. Journal of Lipid Research, 44 (9) pp. 1652-1659.
The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation.
Fajas L., Egler V., Reiter R., Hansen J., Kristiansen K., Debril M.B., Miard S., Auwerx J., 2002. Developmental Cell, 3 (6) pp. 903-910.
Cyclin A is a mediator of p120E4F-dependent cell cycle arrest in G1.
Fajas L., Paul C., Vié A., Estrach S., Medema R., Blanchard J.M., Sardet C., Vignais M.L., 2001. Molecular and Cellular Biology, 21 (8) pp. 2956-2966.
Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis.
Fajas L., Debril M.B., Auwerx J., 2001. Journal of Molecular Endocrinology, 27 (1) pp. 1-9.
PPAR gamma: an essential role in metabolic control.
Fajas L., Debril M.B., Auwerx J., 2001. Nutrition, Metabolism, and Cardiovascular Diseases, 11 (1) pp. 64-69.
The pleiotropic functions of peroxisome proliferator-activated receptor gamma.
Debril M.B., Renaud J.P., Fajas L., Auwerx J., 2001. Journal of Molecular Medicine, 79 (1) pp. 30-47.
A CDE/CHR-like element mediates repression of transcription of the mouse RB2 (p130) gene.
Fajas L., Le Cam L., Polanowska J., Fabbrizio E., Servant N., Philips A., Carnac G., Sardet C., 2000. FEBS Letters, 471 (1) pp. 29-33.
Human E2F5 gene is oncogenic in primary rodent cells and is amplified in human breast tumors.
Polanowska J., Le Cam L., Orsetti B., Vallés H., Fabbrizio E., Fajas L., Taviaux S., Theillet C., Sardet C., 2000. Genes, Chromosomes and Cancer, 28 (1) pp. 126-130.
Impact of the Peroxisome Proliferator Activated Receptor gamma2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus.
Meirhaeghe A., Fajas L., Helbecque N., Cottel D., Auwerx J., Deeb S.S., Amouyel P., 2000. International Journal of Obesity and Related Metabolic Disorders, 24 (2) pp. 195-199.
pRB binds to and modulates the transrepressing activity of the E1A-regulated transcription factor p120E4F.
Fajas L., Paul C., Zugasti O., Le Cam L., Polanowska J., Fabbrizio E., Medema R., Vignais M.L., Sardet C., 2000. Proceedings of the National Academy of Sciences of the United States of America, 97 (14) pp. 7738-7743.
The retinoblastoma-like protein p130 is involved in the determination of reserve cells in differentiating myoblasts.
Carnac G., Fajas L., L'honoré A., Sardet C., Lamb N.J., Fernandez A., 2000. Current Biology, 10 (9) pp. 543-546.
Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis.
Saladin R., Fajas L., Dana S., Halvorsen Y.D., Auwerx J., Briggs M., 1999. Cell Growth and Differentiation, 10 (1) pp. 43-48.
Improved LM-PCR procedure for in vivo footprinting analysis of GC-rich promoters.
Le Cam L., Polanowska J., Fajas L., Fabbrizio E., Sardet C., 1999. Biotechniques, 26 (5) pp. 840-843.
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively.
Gelman L., Zhou G., Fajas L., Raspé E., Fruchart J.C., Auwerx J., 1999. Journal of Biological Chemistry, 274 (12) pp. 7681-7688.
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells.
Lefebvre M., Paulweber B., Fajas L., Woods J., McCrary C., Colombel J.F., Najib J., Fruchart J.C., Datz C., Vidal H. et al., 1999. Journal of Endocrinology, 162 (3) pp. 331-340.
Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism.
Fajas L., Schoonjans K., Gelman L., Kim J.B., Najib J., Martin G., Fruchart J.C., Briggs M., Spiegelman B.M., Auwerx J., 1999. Molecular and Cellular Biology, 19 (8) pp. 5495-5503.
A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans.
Meirhaeghe A., Fajas L., Helbecque N., Cottel D., Lebel P., Dallongeville J., Deeb S., Auwerx J., Amouyel P., 1998. Human Molecular Genetics, 7 (3) pp. 435-440.
A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.
Deeb S.S., Fajas L., Nemoto M., Pihlajamäki J., Mykkänen L., Kuusisto J., Laakso M., Fujimoto W., Auwerx J., 1998. Nature Genetics, 20 (3) pp. 284-287.
Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein.
Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., Glass C.K., 1998. Proceedings of the National Academy of Sciences of the United States of America, 95 (13) pp. 7614-7619.
Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes.
Vigouroux C., Fajas L., Khallouf E., Meier M., Gyapay G., Lascols O., Auwerx J., Weissenbach J., Capeau J., Magré J., 1998. Diabetes, 47 (3) pp. 490-492.
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter.
Fajas L., Fruchart J.C., Auwerx J., 1998. FEBS Letters, 438 (1-2) pp. 55-60.
Transcriptional control of adipogenesis.
Fajas L., Fruchart J.C., Auwerx J., 1998. Current Opinion in Cell Biology, 10 (2) pp. 165-173.
Cycle sequencing on large DNA templates.
Fajas L., Staels B., Auwerx J., 1997. Biotechniques, 23 (6) pp. 1034-1036.
The organization, promoter analysis, and expression of the human PPARgamma gene.
Fajas L., Auboeuf D., Raspé E., Schoonjans K., Lefebvre A.M., Saladin R., Najib J., Laville M., Fruchart J.C., Deeb S. et al., 1997. Journal of Biological Chemistry, 272 (30) pp. 18779-18789.
Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients.
Auboeuf D., Rieusset J., Fajas L., Vallier P., Frering V., Riou J.P., Staels B., Auwerx J., Laville M., Vidal H., 1997. Diabetes, 46 (8) pp. 1319-1327.
El test de liberación de histamina como parámetro diagnóstico y su posible modificación post inmunoterapia específica
Engel P., Malet A., Sanosa J., Fajas L., García-Calderón P.A., 1985. Allergologia et Immunopathologia, 13 (2) pp. 93-100.
Transparent     Swiss University
Unicentre  -  CH-1015 Lausanne  -  Suisse  -  Tél. +41 21 692 11 11  -  Fax +41 21 692 20 15